W

Wellington Management

Global asset management for institutional clients

Fund Product Analyst

Full-TimeUpdated on 10/24/2026
No salary listed
Mid
London, UK
HybridHybrid: employees work in the office 4 days a week and may work remotely 1 day a week.
Project & Program ManagementProject Management

About the job

Requirements
  • At least 3 years of experience working in asset management or a related industry.
  • Hands-on experience with legal or regulatory documents and content creation is valued; direct experience in a product or legal role and proximity to fund vehicles are highly valued.
  • Project management experience.
  • Exceptional organizational skills and attention to detail.
  • Excellent written and verbal communication skills, including the ability to simplify complex information.
  • Willingness to take initiative and demonstrate accountability and ownership, with judgment about when to seek wider input.
  • Ability to navigate cross-functional projects and establish healthy working relationships.
Responsibilities
  • Lead and project-manage the end-to-end prospectus process for various fund ranges and domiciles, including new fund approvals and discretionary or regulatory-driven fund changes, working with external legal counsel and regulators to obtain approval.
  • Evolve the prospectus process to improve efficiency as the business expands into new distribution markets, including Asia retail registrations for cross-border UCITS funds.
  • Establish consistency and quality across fund offering documents, including shareholder notices, and help embed control and oversight processes with stakeholders, legal counsel, external counsel, and vendors, aiming for consistent, improved client-friendly disclosures and communications.
  • Coordinate documentation updates, including prospectuses, internal governance communications, KIID/KID, and regulatory forms, ensuring the appropriate documents are generated, language is consistent, and materials are delivered on time for governance meetings.
  • Coordinate responses to regulator comments across concurrent submissions, convey urgency to subject matter experts, and help ensure responses are accurate.
  • Help draft client notifications and incorporate required notice periods into master schedules.
  • Own relationships with external vendors responsible for registration and publication of prospectuses, shareholder notices, and other fund documentation.
  • Coordinate periodic internal communications summarizing upcoming changes and implementation items for affected stakeholder groups, involving subject matter experts as needed.
  • Provide fund expertise and act as a subject matter expert for internal stakeholders handling client-specific queries that client or fund service teams cannot address, including queries about fund documentation changes and shareholder communications.
  • Lead or assist with Fund Product projects, including annual fee and prospectus reviews with investment teams and industry data to assess fee competitiveness and alignment between prospectuses and fund management.
  • Review seed capital and share classes to support responsible stewardship of firm resources.
  • Assist with management of European MiFID Template and European ESG Template production and dissemination, ensuring distributors receive information needed for their MiFID II obligations.
  • Support commercial and fiduciary reviews of the fund range to assess whether funds are scaling as expected and maintaining a diversified client base.
Desired Qualifications
  • A desire to develop as an individual contributor and, over time, take on more responsibility for components of the fund lifecycle process.

About the company

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$65.9B

Headquarters

Boston, Massachusetts

Founded

1933

Get referred to Wellington Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hartford Funds acquisition closes in first quarter 2027, adding wealth distribution.
  • The new Wellington-Vanguard-Blackstone solutions expand access to public-private portfolios.
  • Wellington’s venture, biotech, climate, and CLO launches broaden fee-bearing alternatives.

What critics are saying

  • Hartford Funds integration carries execution risk until regulators approve the Q1 2027 close.
  • Steve Klar’s retirement in June 2026 exposes client-platform succession risk.
  • Passive giants and private-credit rivals compress Wellington’s fees and threaten AUM growth.

What makes Wellington Management unique

  • Wellington blends public and private markets through alliances with Vanguard and Blackstone.
  • Its $1.35 trillion platform spans 60 countries and over 2,500 institutional clients.
  • Matt Witheiler’s Forbes Midas List streak validates Wellington’s late-stage growth investing credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Comprehensive health coverage
  • Work-life balance
  • Financial future
  • Development

Company News

wallstreet:online AG
Oct 23rd, 2026
Zai Lab raises $250M in TCGX-led PIPE to fund cancer drug zoci

Zai Lab, a biopharma company listed on Nasdaq and the Hong Kong exchange, has agreed to raise about $250 million in a private placement. It will sell 11,340,000 American Depositary Shares at $22.04 each, with each share representing ten ordinary shares. TCGX leads the round. Other investors include abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Sirenia Capital Management, Wellington Management, and Woodline Partners. Zai Lab will mainly use the proceeds to support global development of zocilurtatug pelitecan, its DLL3-targeting antibody-drug conjugate. The deal is expected to close on or about October 27, 2026.

The Information
Oct 15th, 2026
Mueon raises $65M to pack up to 10x more AI computing into data centres

Portland-based startup Mueon has raised $65 million to develop a new way to arrange AI server rack components. The company says its design could fit up to 10 times more computing capacity into the same amount of power as existing data centre setups. The approach could ease constraints on global computing capacity.

Business Wire
Oct 13th, 2026
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

MarketScreener
Oct 13th, 2026
Alaunos Therapeutics to raise $350M in private placement led by Fairmount

Alaunos Therapeutics has agreed to raise about $349.95 million through a private placement of stock. It signed a Securities Purchase Agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C preferred stock at $1,435.70 per share. The common stock brings in about $987,459, and the preferred stock about $348.97 million. The deal is expected to close on October 14, 2026, subject to customary closing conditions. Fairmount led the placement of Series C non-voting convertible preferred stock. Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management, ADAR1 Capital Management and other firms took part.

LinkedIn
Sep 30th, 2026
We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand… | Mati Staniszewski | 89 comments

We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers'​ Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn